Insights into Doublet Therapy and Clinical Trial Takeaways for Metastatic Prostate Cancer Treatment : Episode 6
Opinion
Video
Key Findings From ARANOTE: Darolutamide Plus ADT in mHSPC
Author(s):
Key Takeaways
- Darolutamide addition to ADT significantly improved progression-free survival in metastatic hormone-sensitive prostate cancer patients compared to placebo.
- The trial highlighted darolutamide's favorable safety profile, supporting its use in combination with ADT.
The panelist discusses how the ARANOTE trial demonstrated significant benefits of adding darolutamide to androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer, showing improvements in radiographic progression-free survival and other key outcomes.
EP: 1.Therapeutic Combination Therapies for Metastatic Prostate Cancer
EP: 2.Patient-Centered Approach to Use of Chemotherapy in Metastatic Prostate Cancer
EP: 3.Inclusion of Chemotherapy and Impact on Outcomes From the ARASENS Trial
EP: 4.Patient Selection for Chemotherapy-Based Combination Regimens in Metastatic Prostate Cancer
EP: 5.Clinical Perspectives from the ARANOTE Trial in Metastatic Hormone-Sensitive Prostate Cancer
Now Viewing
EP: 6.Key Findings From ARANOTE: Darolutamide Plus ADT in mHSPC
Video Content above is prompted by the following:
- Discuss the findings of the ARANOTE trial (NCT04736199), which compared the addition of darolutamide or placebo to androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
Related Videos
Related Content
